In the latest session, Cidara Therapeutics Inc (NASDAQ: CDTX) closed at $0.66 down -4.34% from its previous closing price of $0.69. In other words, the price has decreased by -$0.0300 from its previous closing price. On the day, 534642 shares were traded.
Ratios:
For a deeper understanding of Cidara Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.55 and its Current Ratio is at 1.62. In the meantime, Its Debt-to-Equity ratio is 0.54 whereas as Long-Term Debt/Eq ratio is at 0.41.
On September 22, 2021, WBB Securities Upgraded its rating to Strong Buy which previously was Buy but kept the price unchanged to $6.25.
On March 04, 2021, Aegis Capital started tracking the stock assigning a Buy rating and target price of $9.Aegis Capital initiated its Buy rating on March 04, 2021, with a $9 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 11 ’23 when Sandison Taylor sold 18,793 shares for $0.95 per share. The transaction valued at 17,810 led to the insider holds 363,757 shares of the business.
Tari Leslie sold 18,469 shares of CDTX for $17,509 on Sep 11 ’23. The CHIEF SCIENTIFIC OFFICER now owns 275,710 shares after completing the transaction at $0.95 per share. On Aug 14 ’23, another insider, Tari Leslie, who serves as the CHIEF SCIENTIFIC OFFICER of the company, bought 10,000 shares for $0.97 each. As a result, the insider paid 9,700 and bolstered with 294,179 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDTX now has a Market Capitalization of 63.33M and an Enterprise Value of 19.02M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.06 while its Price-to-Book (P/B) ratio in mrq is 7.44. Its current Enterprise Value per Revenue stands at 0.34 whereas that against EBITDA is -0.62.
Stock Price History:
Over the past 52 weeks, CDTX has reached a high of $2.10, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is 0.7145, while the 200-Day Moving Average is calculated to be 0.8904.
Shares Statistics:
For the past three months, CDTX has traded an average of 682.99K shares per day and 323.94k over the past ten days. A total of 90.62M shares are outstanding, with a floating share count of 82.64M. Insiders hold about 8.80% of the company’s shares, while institutions hold 29.88% stake in the company. Shares short for CDTX as of Feb 15, 2024 were 463.32k with a Short Ratio of 0.68, compared to 623.83k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.51% and a Short% of Float of 0.52%.
Earnings Estimates
There are 3 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.1 for the current quarter, with a high estimate of -$0.07 and a low estimate of -$0.16, while EPS last year was -$0.19. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.28 and -$0.36 for the fiscal current year, implying an average EPS of -$0.31. EPS for the following year is -$0.58, with 3 analysts recommending between -$0.38 and -$0.7.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $11.54M this quarter.It ranges from a high estimate of $14M to a low estimate of $6.7M. As of the current estimate, Cidara Therapeutics Inc’s year-ago sales were $10.22M, an estimated increase of 12.90% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $13.05M, a decrease of -49.80% less than the figure of $12.90% in the same quarter last year. There is a high estimate of $14.5M for the next quarter, whereas the lowest estimate is $11.6M.
A total of 3 analysts have provided revenue estimates for CDTX’s current fiscal year. The highest revenue estimate was $60.3M, while the lowest revenue estimate was $53M, resulting in an average revenue estimate of $57.85M. In the same quarter a year ago, actual revenue was $64.29M, down -10.00% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $21.07M in the next fiscal year. The high estimate is $29.5M and the low estimate is $5.8M. The average revenue growth estimate for next year is down -63.60% from the average revenue estimate for this year.
